CNS Drugs

, Volume 26, Issue 8, pp 649–662

Venous Thromboembolism in Recipients of Antipsychotics

Incidence, Mechanisms and Management
Review Article


Since chlorpromazine was introduced to the market in the early 1950s, the use of antipsychotic drugs has been associated with venous thromboembolism (VTE) in a number of reports. During the last decade the evidence has been strengthened with large epidemiological studies. Whether all antipsychotics increase the risk for VTE or the risk is confined to certain drugs is still unclear. The aim of this article is to present an updated critical review focusing on the incidence, mechanisms and management of VTE in users of antipsychotics. After searching the databases PubMed and Scopus for relevant articles we identified 12 observational studies, all of which were published after the year 2000. In most of these studies an elevated risk of VTE was observed for antipsychotic drugs, with the highest risk for clozapine, olanzapine and low-potency first-generation antipsychotics. The risk seems to be correlated with dose. The elderly, who mainly use lower doses, do not show an increased risk of VTE to the same extent as younger subjects.

The underlying biological mechanisms explaining the association between antipsychotic medication and VTE are to a large extent unknown. Several hypotheses have been proposed, such as body weight gain, sedation, enhanced platelet aggregation, increased levels of antiphospholipid antibodies, hyperprolactinaemia and hyperhomocysteinaemia. The risk of VTE in schi-zophrenia and other psychotic disorders may also be related to the underlying disease rather than the medication.

Very limited evidence exists to guide how cases of VTE in subjects using antipsychotics should be handled. An attempt to compile an algorithm where the patients’ individual risk of VTE is assessed and preventive clinical measures are suggested has been published recently. Strong consideration should be given to discontinuation of the offending antipsychotic drug in patients experiencing a VTE, and another antipsychotic drug with a presumably lower risk should be chosen if antipsychotic drug treatment is still indicated. It is essential that physicians and patients are aware that VTE may be an adverse drug reaction to the antipsychotic treatment so the condition is identified early and treated appropriately.


  1. 1.
    Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005 Mar 26–Apr 1; 365(9465): 1163–74PubMedCrossRefGoogle Scholar
  2. 2.
    Liem TK, Deloughery TG. First episode and recurrent venous thromboembolism: who is identifiably at risk? Semin Vasc Surg 2008 Sep; 21(3): 132–8PubMedCrossRefGoogle Scholar
  3. 3.
    Ageno W, Squizzato A, Garcia D, et al. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 2006 Oct; 32(7): 651–8PubMedCrossRefGoogle Scholar
  4. 4.
    Brehmer G, Ruckdeschel KT. Technic of the hibernation therapy [in German]. Dtsch Med Wochenschr 1953 Dec 11; 78(50): 1724–5PubMedCrossRefGoogle Scholar
  5. 5.
    Labhardt F. Technic, side effects and complications of largactil therapy [in German]. Schweiz Arch Neurol Psychiatr 1954; 73(1–2): 338–45PubMedGoogle Scholar
  6. 6.
    Grahmann H, Suchenwirth R. Thrombosis hazard in chlorpromazine and reserpine therapy of endogenous psychoses [in German]. Nervenarzt 1959 May 20; 30(5): 224–5PubMedGoogle Scholar
  7. 7.
    Hägg S, Bate A, Ståhl M, et al. Associations between venous thromboembolism and antipsychotics: a study of the WHO database of adverse drug reactions. Drug Saf 2008; 31(8): 685–94PubMedCrossRefGoogle Scholar
  8. 8.
    Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997 Nov;8(6):671–7PubMedGoogle Scholar
  9. 9.
    Hägg S, Spigset O, Söderström TG. Association of venous thromboembolism and clozapine. Lancet 2000 Apr 1; 355(9210): 1155–6PubMedCrossRefGoogle Scholar
  10. 10.
    Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000 Oct 7; 356(9237): 1219–23PubMedCrossRefGoogle Scholar
  11. 11.
    Modai I, Hirschmann S, Rava A, et al. Sudden death in patients receiving clozapine treatment: a preliminary investigation. J Clin Psychopharmacol 2000 Jun; 20(3): 325–7PubMedCrossRefGoogle Scholar
  12. 12.
    Parkin L, Skegg DC, Herbison GP, et al. Psychotropic drugs and fatal pulmonary embolism. Pharmacoepidemiol Drug Saf 2003 Dec; 12(8): 647–52PubMedCrossRefGoogle Scholar
  13. 13.
    Hamanaka S, Kamijo Y, Nagai T, et al. Massive pulmonary thromboembolism demonstrated at necropsy in Japanese psychiatric patients treated with neuroleptics including atypical antipsychotics. Circ J 2004 Sep; 68(9): 850–2PubMedCrossRefGoogle Scholar
  14. 14.
    Liperoti R, Pedone C, Lapane KL, et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005 Dec 12–26; 165(22): 2677–82PubMedCrossRefGoogle Scholar
  15. 15.
    Masopust J, Maly R, Urban A, et al. Antipsychotic drugs as a risk factor for venous thromboembolism. Int J Psychiatr Clin Pract 2006; 11(3): 246–9CrossRefGoogle Scholar
  16. 16.
    Lacut K, Le Gal G, Couturaud F, et al. Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol 2007 Dec; 21(6): 643–50PubMedCrossRefGoogle Scholar
  17. 17.
    Ray JG. Hyperhomocysteinemia: no longer a consideration in the management of venous thromboembolism. Curr Opin Pulm Med 2008 Sep; 14(5): 369–73PubMedCrossRefGoogle Scholar
  18. 18.
    Jönsson AK, Brudin L, Ahlner J, et al. Antipsychotics associated with pulmonary embolism in a Swedish medicolegal autopsy series. Int Clin Psychopharmacol 2008 Sep; 23(5): 263–8PubMedCrossRefGoogle Scholar
  19. 19.
    Jönsson AK, Horvath-Puho E, Hägg S, et al. Antipsychotics and risk of venous thromboembolism: a population-based case-control study. Clin Epidemiol 2009; 1: 19–26PubMedGoogle Scholar
  20. 20.
    Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic medication and venous thrombosis. Br J Psychiatry 2001 Jul; 179: 63–6PubMedCrossRefGoogle Scholar
  21. 21.
    Knudson JF, Kortepeter C, Dubitsky GM, et al. Antipsychotic drugs and venous thromboembolism [letter]. Lancet 2000 Jul 15; 356(9225): 252–3PubMedCrossRefGoogle Scholar
  22. 22.
    Wolstein J, Grohmann R, Rüther E, et al. Antipsychotic drugs and venous thromboembolism [letter]. Lancet 2000 Jul 15; 356(9225): 252PubMedCrossRefGoogle Scholar
  23. 23.
    Hägg S, Tätting P, Spigset O. Olanzapine and venous thromboembolism. Int Clin Psychopharmacol 2003 Sep; 18(5): 299–300PubMedCrossRefGoogle Scholar
  24. 24.
    Malý R, Masopust J, Hosak L, et al. Four cases of venous thromboembolism associated with olanzapine. Psychiatry Clin Neurosci 2009 Feb; 63(1): 116–8PubMedCrossRefGoogle Scholar
  25. 25.
    Hägg S, Jönsson AK, Spigset O. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opin Drug Saf 2009 Sep; 8(5): 537–47PubMedCrossRefGoogle Scholar
  26. 26.
    Hägg S, Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs 2002; 16(11): 765–76PubMedCrossRefGoogle Scholar
  27. 27.
    Paciullo CA. Evaluating the association between clozapine and venous thromboembolism. Am J Health Syst Pharm 2008 Oct 1; 65(19): 1825–9PubMedCrossRefGoogle Scholar
  28. 28.
    Maly R, Masopust J, Hosák L, et al. Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients. Psychiatry Clin Neurosci 2007; 62: 3–8CrossRefGoogle Scholar
  29. 29.
    Van Neste EG, Verbruggen W, Leysen M. Deep venous thrombosis and pulmonary embolism in psychiatric settings. Eur J Psychiat 2009; 23(1): 19–30Google Scholar
  30. 30.
    Toringhibel M, Adam T, Arghir OC, et al. Acute massive pulmonary embolism associated with olanzapine therapy and no significant personal history in a young male: case report and literature review. Pneumologia 2011 Apr–Jun; 60(2): 82–4PubMedGoogle Scholar
  31. 31.
    Allenet B, Schmidlin S, Genty C, et al. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf 2012 Jan; 21(1): 42–8PubMedCrossRefGoogle Scholar
  32. 32.
    Kleijer BC, Heerdink ER, Egberts TC, et al. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients. J Clin Psychopharmacol 2010 Oct; 30(5): 526–30PubMedCrossRefGoogle Scholar
  33. 33.
    Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 2010; 341: c4245PubMedCrossRefGoogle Scholar
  34. 34.
    Zhang R, Dong L, Shao F, et al. Antipsychotics and venous thromboembolism risk: a meta-analysis. Pharmacopsychiatry 2011 Jul; 44(5): 183–8PubMedCrossRefGoogle Scholar
  35. 35.
    Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematology Am Soc Hematol Educ Program 2005: 1–12Google Scholar
  36. 36.
    Huerta C, Johansson S, Wallander MA, et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007 May 14; 167(9): 935–43PubMedCrossRefGoogle Scholar
  37. 37.
    Muench J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Physician 2010 Mar 1; 81(5): 617–22PubMedGoogle Scholar
  38. 38.
    Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005 Nov 5; 366(9497): 1640–9PubMedCrossRefGoogle Scholar
  39. 39.
    Gustafsson F, Kragelund CB, Torp-Pedersen C, et al. Effect of obesity and being overweight on long-term mortality in congestive heart failure: influence of left ventricular systolic function. Eur Heart J 2005 Jan; 26(1): 58–64PubMedCrossRefGoogle Scholar
  40. 40.
    Anderson Jr FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003 Jun 17; 107(23 Suppl 1): 16–19Google Scholar
  41. 41.
    Hägg S, Lindblom Y, Mjörndal T, et al. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006 Mar; 21(2): 93–8PubMedCrossRefGoogle Scholar
  42. 42.
    Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999 Nov; 156(11): 1686–96PubMedGoogle Scholar
  43. 43.
    Urban A, Masopust J, Maly R, et al. Prolactin as a factor for increased platelet aggregation. Neuro Endocrinol Lett 2007 Aug; 28(4): 518–23PubMedGoogle Scholar
  44. 44.
    Wallaschofski H, Eigenthaler M, Kiefer M, et al. Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. J Clin Psychopharmacol 2003 Oct; 23(5): 479–83PubMedCrossRefGoogle Scholar
  45. 45.
    Wallaschofski H, Donne M, Eigenthaler M, et al. PRL as a novel potent cofactor for platelet aggregation. J Clin Endocrinol Metab 2001 Dec; 86(12): 5912–9PubMedCrossRefGoogle Scholar
  46. 46.
    Rousseau AM. Hyperprolactinemia and atypical antipsychotic therapy in a case of fatal thromboembolism. J Clin Psychopharmacol 2010 Dec; 30(6): 734–5PubMedCrossRefGoogle Scholar
  47. 47.
    O’Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 2008 Mar; 22(2 Suppl.): 70–5PubMedCrossRefGoogle Scholar
  48. 48.
    Axelsson S, Hägg S, Eriksson AC, et al. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin Exp Pharmacol Physiol 2007 Aug; 34(8): 775–80PubMedCrossRefGoogle Scholar
  49. 49.
    Schedel A, Thornton S, Kluter H, et al. The effect of psychoactive drugs on in vitro platelet function. Transfus Med Hemother 2010; 37(5): 293–8PubMedCrossRefGoogle Scholar
  50. 50.
    Dietrich-Muszalska A, Rabe-Jablonska J, Olas B. The effects of the second generation antipsychotics and a typical neuroleptic on collagen-induced platelet aggregation in vitro. World J Biol Psychiatry 2010 Mar; 11(2 Pt 2): 293–9PubMedCrossRefGoogle Scholar
  51. 51.
    Dietrich-Muszalska A, Rabe-Jablonska J, Nowak P, et al. The first- and second-generation antipsychotic drugs affect ADP-induced platelet aggregation. World J Biol Psychiatry 2010 Mar; 11(2 Pt 2): 268–75PubMedCrossRefGoogle Scholar
  52. 52.
    De Clerck F, Somers Y, Mannaert E, et al. In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysis. Clin Ther 2004 Aug; 26(8): 1261–73PubMedCrossRefGoogle Scholar
  53. 53.
    Masopust J, Maly R, Andrys C, et al. Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study. BMC Psychiatry 2011; 11:2PubMedCrossRefGoogle Scholar
  54. 54.
    Schwartz M, Rochas M, Toubi E, et al. The presence of lupus anticoagulant and anticardiolipin antibodies in patients undergoing long-term neuroleptic treatment. J Psychiatry Neurosci 1999 Sep; 24(4): 351–2PubMedGoogle Scholar
  55. 55.
    Lillicrap MS, Wright G, Jones AC. Symptomatic antiphospholipid syndrome induced by chlorpromazine. Br J Rheumatol 1998 Mar; 37(3): 346–7PubMedCrossRefGoogle Scholar
  56. 56.
    Sairam S, Baethge BA, McNearney T. Analysis of risk factors and comorbid diseases in the development of thrombosis in patients with anticardiolipin antibodies. Clin Rheumatol 2003 Feb; 22(1): 24–9PubMedCrossRefGoogle Scholar
  57. 57.
    Ayuso J, Saiz Ruiz J. Neuroleptic-induced antinuclear antibodies. Eur Psychiatry 1996; 11(7): 378–9PubMedCrossRefGoogle Scholar
  58. 58.
    Canoso RT, de Oliveira RM, Nixon RA. Neurolepticassociated autoantibodies: a prevalence study. Biol Psychiatry 1990 Apr 15; 27(8): 863–70PubMedCrossRefGoogle Scholar
  59. 59.
    Canoso RT, de Oliveira RM. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis. Am J Hematol 1988 Apr; 27(4): 272–5PubMedCrossRefGoogle Scholar
  60. 60.
    Metzer WS, Canoso RT, Newton JE. Anticardiolipin antibodies in a sample of chronic schizophrenics receiving neuroleptic therapy. South Med J 1994 Feb; 87(2): 190–2PubMedCrossRefGoogle Scholar
  61. 61.
    Steen VD, Ramsey-Goldman R. Phenothiazine-induced systemic lupus erythematosus with superior vena cava syndrome: case report and review of the literature. Arthritis Rheum 1988 Jul; 31(7): 923–6PubMedCrossRefGoogle Scholar
  62. 62.
    el-Mallakh RS, Donaldson JO, Kranzler HR, et al. Phenothiazine-associated lupus anticoagulant and thrombotic disease. Psychosomatics 1988 Winter; 29(1): 109–13PubMedCrossRefGoogle Scholar
  63. 63.
    Davis S, Kern HB, Asokan R. Antiphospholipid antibodies associated with clozapine treatment. Am J Hematol 1994 Jun; 46(2): 166–7PubMedCrossRefGoogle Scholar
  64. 64.
    Shen H, Li R, Xiao H, et al. Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients. J Psychiatr Res 2009 Mar; 43(6): 615–9PubMedCrossRefGoogle Scholar
  65. 65.
    Halacheva K, Dimova S, Tolev T, et al. Elevated anticardiolipin antibodies in schizophrenic patients before and during neuroleptic medication. Psychiatry Res 2009 Aug 30; 169(1): 51–5PubMedCrossRefGoogle Scholar
  66. 66.
    Firer M, Sirota P, Schild K, et al. Anticardiolipin antibodies are elevated in drug-free, multiply affected families with schizophrenia. J Clin Immunol 1994 Jan; 14(1): 73–8PubMedCrossRefGoogle Scholar
  67. 67.
    Chengappa KN, Carpenter AB, Keshavan MS, et al. Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients. Biol Psychiatry 1991 Oct 1; 30(7): 731–5PubMedCrossRefGoogle Scholar
  68. 68.
    Roche-Bayard P, Rossi R, Mann JM, et al. Left pulmonary artery thrombosis in chlorpromazine-induced lupus [letter]. Chest 1990 Dec; 98(6): 1545PubMedCrossRefGoogle Scholar
  69. 69.
    Haidemenos A, Kontis D, Gazi A, et al. Plasma homocysteine, folate and B12 in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007 Aug 15; 31(6): 1289–96PubMedCrossRefGoogle Scholar
  70. 70.
    Henderson DC, Copeland PM, Nguyen DD, et al. Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. Acta Psychiatr Scand 2006 Feb; 113(2): 121–5PubMedCrossRefGoogle Scholar
  71. 71.
    Vuksan-Cusa B, Jakovljevic M, Sagud M, et al. Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with second generation antipsychotics. Psychiatry Res 2011 Aug 30; 189(1): 21–5PubMedCrossRefGoogle Scholar
  72. 72.
    Eldibany MM, Caprini JA. Hyperhomocysteinemia and thrombosis: an overview. Arch Pathol Lab Med 2007 Jun; 131(6): 872–84PubMedGoogle Scholar
  73. 73.
    Schneede J, Refsum H, Ueland PM. Biological and environmental determinants of plasma homocysteine. Semin Thromb Hemost 2000; 26(3): 263–79PubMedCrossRefGoogle Scholar
  74. 74.
    Reif A, Schneider MF, Kamolz S, et al. Homocysteinemia in psychiatric disorders: association with dementia and depression, but not schizophrenia in female patients. J Neural Transm 2003 Dec; 110(12): 1401–11PubMedCrossRefGoogle Scholar
  75. 75.
    Cattaneo M. Hyperhomocysteinemia and venous thromboembolism. Semin Thromb Hemost 2006 Oct; 32(7): 716–23PubMedCrossRefGoogle Scholar
  76. 76.
    Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thrombo-prophylaxis in medical patients. Thromb Haemost 2005 Oct; 94(4): 750–9PubMedGoogle Scholar
  77. 77.
    De Hert M, Einfinger G, Scherpenberg E, et al. The prevention of deep venous thrombosis in physically restrained patients with schizophrenia. Int J Clin Pract 2010 Jul; 64(8): 1109–15PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Anna K. Jönsson
    • 1
    • 2
  • Olav Spigset
    • 3
    • 4
  • Staffan Hägg
    • 1
    • 2
  1. 1.Department of Drug Research/Clinical Pharmacology, Faculty of Health SciencesLinköping UniversityLinköpingSweden
  2. 2.Department of Clinical PharmacologyCounty Council of LinköpingLinköpingSweden
  3. 3.Department of Clinical PharmacologySt. Olav University HospitalTrondheimNorway
  4. 4.Department of Laboratory Medicine, Children’s and Women’s HealthNorwegian University of Science and TechnologyTrondheimNorway

Personalised recommendations